Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-UMIN000021336
JPRN-UMIN000021336
Completed
Phase 1

Phase 1 study to evaluate the safety and efficacy of jyuzentaihoto in infantile anal fistula - Safety and efficacy of jyuzentaihoto in infantile anal fistula

Kanazawa University0 sites20 target enrollmentMarch 4, 2016
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsinfantile anal fistula

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
infantile anal fistula
Sponsor
Kanazawa University
Enrollment
20
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 4, 2016
End Date
August 31, 2016
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • •Any of the following: currently receiving a drug therapy, currently having chronic diseases such as heart, lung, kidney, gastrointestinal, and inflammatory diseases, suffering from invasive cancer within five years, suffering from non\-invasive cancer within a year, and having taken Kampo medicine within 2 weeks.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Gene therapy study with autologous hemapoietic stem cells for patients affected by MPSIH
EUCTR2017-002430-23-ITOSPEDALE SAN RAFFAELE6
Active, not recruiting
Phase 1
Gene therapy study with autologous hemapoietic stem cells for patients affected by MPSIHMucopolysaccharidosis type I HurlerTherapeutic area: Phenomena and Processes [G] - Genetic Phenomena [G05]
CTIS2024-514870-29-00Ospedale San Raffaele S.r.l.8
Active, not recruiting
Phase 1
Studio di terapia genica con cellule staminali ematopoietiche autologhe
EUCTR2014-004860-39-ITOSPEDALE SAN RAFFAELE10
Completed
Phase 1
A clinical trial to study safety and effects of P276-00 in combination with Gemcitabine in treatment of pancreatic cancer .
CTRI/2009/091/000214Piramal Life Sciences Limited23
Active, not recruiting
Phase 1
Evaluation of safety and efficacy of DCVAC/LuCa (immunotherapy of lung cancer) in patients with metastatic lung cancerStage IV Non-Small Cell Lung CancerMedDRA version: 20.1Level: PTClassification code 10025070Term: Lung carcinoma cell type unspecified stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
EUCTR2014-003084-37-CZSOTIO a.s.98